INTRODUCTION
Tumors of the skeletal muscles, or rhabdomyosarcomas, are unusual in adults but common in children, probably occurring as frequently as Wilms' tumor." Although they may be found at virtually any site, they show a predilection for certain locations, particularly the head and neck, extremity, and genitourinary areas. Histologic diagnosis is often difficult because of the tumor's resemblance to other malignancies.
. Within decades, rhabdomyosarcoma, after being a rapidly fatal cancer, has become one that is often controlled and occasionally cured. Because it occurs primarily in children, . the effect of therapy in extending useful life becomes magnified out of proportion to the tumor's rarity. It provides a major example of the effectiveness of multimodality therapy and demonstrates again the importance of proper pretreatment staging. Since there are several excellent recent reviews of the tumor in general.!" we shall consider only rhabdomyosarcomas of the head and neck.
INCIDENCE
Rhabdomyosarcoma represents 5 percent of l l pediatric malignancies and is the most common soft-tissue sarcoma of childhood. Its annual iricidence is estimated to be 5.7 per million in children under 15 years of age in the United States." It occurs three to three and a half times more frequently in whites than in nonwhites and is slightly more common in males than in females. Seventy percent of rhabdomyosarcomas occur in children less than 10 years old, with the peak incidence between the ages of two and five. Beyond 15 years of age, rhabdomyosarcoma is rare. The head-and-neck region (including the orbit) accounts for 36 to 41 percent of When a cold* strikes 238,857 miles from home,a decon estant can't.afford to ail.
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all rhabdomyosarcomas, making this region the most common primary site of involvement. 3, 5, 7, 8 Among 308 children enrolled in a cooperative group, the Intergroup Rhabdomyosarcoma Study, 109 tumors (35 percent) occurred in the head and neck." According to this and similar reports;' the orbit is the most common primary site-with the ear, neck, nasopharynx, and larynx affected in decreasing order of frequency.
PATHOLOGY
Grossly, rhabdomyosarcomas are soft, fleshy, and often pink or gray-pink, depending on the degree of necrosis. Histologically, there are three major types: pleomorphic, embryonal, and alveolar. 3, 9 The pleomorphic variety is composed largely of spindle cells, often with cross-striations, It does not correspond to a stage of development of normal muscle tissue but' resembles dedifferentiated adult striated muscle. This type, which is rare, is seen largely in adults.
The embryonal rhabdomyosarcomas consist of small, round, and spindle-shaped cells and are often mistaken for other tumors, such as neuroblastoma, retinoblastoma, Ewing's sarcoma, and non-Hodgkin's lymphoma. This type of rhabdomyosarcoma closely resembles developing muscle in the seven-to-l Ovweek fetus and is the most common variant in children. The so-called botryoid rhabdomyosarcoma does not merit designation as a separate subtype and describes only the gross appearance of the tumor. Histologically, it should be considered an embryonal rhabdomyosarcoma. Alveolar rhabdomyosarcoma is characterized by cells that may be aligned in clusters, producing a superficial resemblance to adenocarcinoma. This variant is the least common and resembles normal fetal muscle development at 10 to 12 weeks of gestation.
Recently, the Pathology Evaluation Committee of the Intergroup Rhabdomyosarcoma Study reported two additional histologic subtypes. 10 In the past these were referred to as "soft-tissue Ewing's sarcoma," because of their histologic resemblance to that bone tumor. Type I corre- sponds to the conventional Ewing's tumor, while type II refers to the histologic variant called "large-cell Ewing's tumor."
The histologic diagnosis of rhabdomyosarcoma is often difficult, and in a significant number of cases it is confused with other benign and malignant neoplasms, such as lymphoma and neuroblastoma." It is essential that carefully prepared biopsy sections-stained with hematoxylin-eosin, periodic acid-Schiff, and PAS after diastase digestion-be examined by an experienced pathologist. Ultrastructural studies of the biopsy specimen are frequently necessary for accurate diagnosis. Thus, appropriate samples should be prepared for electron microscopy in every instance.
PRESENTATION
Rhabdomyosarcomas are great mimics and display a wide variety of clinicalmanifestations. 11 Lesions of the orbit, the most frequent site of involvement, may appear as eyelid masses, with subtle discoloration of the skin, initially resembling hordeolum or chalazion. If conservative management of an apparently infectious lesion of the eyelid fails, rhabdomyosarcoma should be considered. Intraorbital rhabdomyosarcoma frequently presents dramatically, with obvious ptosis, proptosis, ecchymosis of the eyelid, and limitation of function of the extraocular muscles (Figures 1 and 2 ). An unremitting otitis media, bloody aural discharge, and/ or a polyp-Volume 59, April 1980 oid mass extruding from the external auditory canal, particularly when associated with pain, should suggest a rhabdomyosarcoma of the middle ear. 12 With extension from the middle ear, cranial nerves may be affected; paralysis of the seventh cranial nerve is particularly common. A slowly enlarging, painless mass may be the only manifestation of rhabdomyosarcoma when it occurs in the soft tissues of the face or (Figure 3) , where it is frequently accompanied by unilateral facial weakness and cervical-and brachial-plexus palsies. In the nasooropharynx, rhabdomyosarcomas produce upper-airway obstruction, with epistaxis, dysphagia, and a visible polyplike mass on physical examination ( Figure 4 ). 13 Of major importance is the recent finding by the Intergroup Rhabdomyosarcoma Study that in 35 percent of patients with tumors in the parameningeal areas (such as nasopharynx, middle ear, paranasal sinuses, and nasal cavity), the tumor extends directly into the central nervous system." Symptoms may include cranial-nerve palsies or respiratory paralysis due to implication of the brain stem, either at the time of diagnosis or (usually) within one year. In contrast, lymph-node metastases are rare, occurring in less than 3 percent of patients with rhabdomyosarcoma of the head and neck and virtually never with primary tumors of the orbit. 3.5 For head-and-neck primary tumors, lung metastases are second in frequency to central-nervous-system involvement. 2 Other sites of metastases include bone, bone marrow, and liver.
EVALUATION
After the histologic diagnosis is established, the extent of the malignancy must be determined (staging). Staging is critical not only for treatment planning but also for determining Localized disease with tumor completely resected and regional nodes not affected a. Confined to muscle or organ of origin b. Contiguous involvement -infiltration outside the muscle or organ of origin, as through fascial planes
Group II
Localized disease with microscopic residual disease or regional disease with no residual or with microscopic residual disease a. Grossly resected tumor with microscopic residual disease b. Regional tumor completely resected c. Regional disease with involved nodes grossly resected but with evidence of microscopic residual disease Patients are divided into four groups on the basis of the extent of disease and of clinical, surgical, and pathologic information. Group I consists of patients with localized tumor that is completely resected, without involvement of regional nodes. Group II designates patients with grossly resected tumor with microscopic residual disease (a), complete resection of regional disease (b), or regional disease resected with microscopic residual disease (c). Group III comprises patients with gross residual dis-Volume 59, April 1980
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ease and group IV those with metastatic disease at diagnosis.
To supplement the information obtained from physical examination, x-ray studies (including midface tomograms) are necessary to determine the extent of the soft-tissue mass. These studies will also help define invasion of surrounding bony structures, such as paranasal sinuses, base of skull, facial bones, and cervical spine. Because of the frequency of meningeal and cerebral extension, examination of the spinal-fluid cytology and computerized axial tomography of the skull are necessary in all cases of parameningeal rhabdomyosarcoma. Distant metastases should be sought by x-ray examination of the chest, by bone and liver scans, and by bone-marrow aspiration.
The stage of 109 patients with head-andneck primary tumors reported by the I.R.S. is shown in Table 2 . 5 Green and jaffe" have reported a similar distribution of patients from other series. It is apparent that most head-and-159 neck rhabdomyosarcomas are advanced (stage III or IV) at the time of diagnosis. This is a key factor in treatment planning.
GENERAL PRINCIPLES OF TREATMENT
Judicious use of the three modalities of surgery, radiation therapy, and chemotherapy has already been demonstrated to improve response rates and to produce cures that previously would have been impossible.s-'v'" Treatment must provide for both local and metastatic disease control. Surgery. The basic principle of surgical approach to management of rhabdomyosarcoma continued is complete resection of the tumor, with an "envelope" of normal tissue when possible."? However, the surrounding anatomic confines of the head-and-neck region do not often permit such a radical approach without extensive disfigurement. Resection of the mass, with microscopic or gross residual disease, or biopsy alone is usually all that is possible. Radiation therapy. Radiation in doses ranging from 4,000 to 6,000 rads to the tumor bed is effective when microscopic or gross residual tumor is present after surgery.t" The radiation dose is determined by the stage of the disease and the age of the patient. Treatment planning should assure protection of the surrounding normal tissues.
Early side effects of radiotherapy to the head and neck include skin changes, mucositis, and salivary-gland swelling. Chronic effects include growth inhibition, cataracts, and chronic dermatitis. Other potential side effects depend on the site irradiated and dose administrated. Chemotherapy. Chemotherapy, particularly with multiple agents, has been very effective and is now used in virtually all treatment programs. Four drugs -vincristine, cyclophosphamide, actinomycin D, and doxorubicin (Adriamycin)-are active, and various combinations of two, three, or four drugs have been used.
For tumor completely resected (group I), the I.R.S. group has shown that the combination of vincristine, actinomycin D, and cyclophosphamide (VAC) for two years has produced a 92 percent disease-free survival rate." Postoperative irradiation produced no added benefit and thus can be eliminated from treatment plans for this group. In patients with group II disease (microscopic residual disease or nodal involvement), two years of treatment with VAC was compared with that with the combination of vincristine and actinomycin D given for one year. All patients in group II received postoperative irradiation. More than 85 percent on each treatment are disease-free at two years: Patients in group III (gross residual disease) and group b.i.d. IV (metastatic disease) have been .treated similarly, with either VAC or VAC plus Adriamycin. Both groups received radiation. The two alternatives seem to produce comparable results, suggesting that the addition of Adriamycin may not be necessary: Seventy-nine percent ofgroup III patients and 50 percent of group IV are still alive.! Chemotherapeutic agents do not discriminate between normal and cancerous tissues and commonly produce toxicity in such constantly renewing tissues as hair follicles, gastrointestinal-tract mucosa, and bone marrow. The almost certain occurrence of alopecia, stomatitis, diarrhea, and myelosuppression is thus not surprising, and these may be severe. Some special toxicities should be mentioned. If extravasated, vincristine, actinomycin 0, and Adriamycin may all cause tissue necrosis. Vincristine causes a peripheral neuropathy with troublesome paresthesias and occasionally ileus, jaw pain, or cranial-nerve palsies. Because of its cardiac toxicity, Adriamycin's use is limited. At doses of greater than 550 mg. /sq. m. (450 mg.! sq. m. if given with cyclophosphamide or mediastinal radiation), it regularly produces a cardiomyopathy. Cyclophosphamide's metabolites may produce hemorrhagic cystitis.
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LONG-ACTING DECONGESTANT REPETABS@TABLETS
Long-term side effects are only now being discovered. It seems clear that both radiation and chemotherapy are carcinogenic, although the magnitude of the problem is not yet appreciated. Long-term genetic effects are also possible. CNS disease. Certain primary sites -notably nasopharynx, nasal cavity, pararrasal sinuses, and middle ear -are at high risk of centralnervous-system extension." Current recommendations are for wide-field radiotherapy alone for these sites if there isnegarive cerebrospinal-fluid cytology, no bony erosion on x-ray, nd no neurologic signs. In the presence of posinve CSF cytology, bony erosion of the base of the skull, or both, craniospinal radiotherapy and intrathecal chemotherapy are recommended. The latter consists of a three-drug program of cytosine. arabinoside, hydrocortisone, and Ear. Here again, total surgical extirpation is not often feasible; the treatment sequence is biopsy, radiotherapy, and chemotherapy. . Other head-and-neck primary sites. Wide excision, when possible, is preferable. It is difficult, however, to achieve microscopic diseasefree margins. In many instances, the only alternative is biopsy. If regional lymph nodes are clinically affected, biopsy is indicated. Because of the low incidence of cervical-lymph-node involvement, extensive procedures (such, as neck dissection) are not usually indicated with- tion is not improved after one week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis extern a, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manltestatlon of sensitization to neomycin is usually a low grade reddening with swelling, dry scaling and itching; it may be manifest simply as a failure to heal. During long-term use of neomycincontaining products, periodic examination for such signs is advisable and the patient should be told to. discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for that patient thereafter. PRECAUTIONS: If sensitization or irritation occurs, medication should be discontinued promptly. Patients who prefer to warm the medication before using should be cautioned against healing the solution above body temperature, in order to avoid loss of potency. Treatment should not be continued for longer than ten days. Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin. ADVERSE REACTIONS: Neomycin is a not uncommon cutaneous sensitizer. There are articles in the CUrrent literature that indicate an increase in the prevalence of persons sensitive' to neomycin. out additional evidence of nodal involvement. 2 Excision is usually followed by radiotherapy to achieve local control and by chemotherapy to control distant metastases.
PROGNOSIS
At this time, only a few features are known to be important in prognosis.2.3.5.21 The most important of these is the extent of the disease at diagnosis. The I.R.S. recently reported twoyear disease-free survivals of 90 percent for clinical group I, 70 to 75 percent for group II, 60 to 65 percent for group III, and 30 percent for group IV. These figures include all primary sites, not just those of the head and neck.
Location of disease is, of course, significant, but less so than the extent of the disease. Ow-Dr.Hakami is AssociateProfessor of Pediatrics and director of pediatric oncologyat the University of Missou· ri-Columbia MedicalCenter.
ing largely to the effectiveness of multimodality therapy, distinctions of prognosis by site are becoming obsolete. Orbital lesions that infiltrate locally, metastasize late, and produce signs and symptoms early have a better prognosis than lesions of the middle ear or nasopharynx. Children less than seven years of age are said to do better than older children.s! Although the alveolar and pleomorphic cell types have been reported to reflect unfavorable histologies, they tend to occur in older children, who often have more advanced disease at diagnosis.
SUMMARY
When prospects for disease control were slim, the managment of rhabdomyosarcoma was less critical. Now, with the prospects of long-term control or cure balanced against the toxicities of several treatment modalities, therapy becomes all-important. The physician who occasionally sees such tumors would be well advised to consult one of the Intergroup Rhabdomyosarcoma Study members. Because of the complexities of the total management, initial evaluation, treatment planning, and follow-up should be done in a setting where oncologist, surgeon, radiation oncologist, pathologist, and other support personnel can contribute their expertise. 0 BIBLIOGRAPHY
